IN2014DN09610A - - Google Patents

Info

Publication number
IN2014DN09610A
IN2014DN09610A IN9610DEN2014A IN2014DN09610A IN 2014DN09610 A IN2014DN09610 A IN 2014DN09610A IN 9610DEN2014 A IN9610DEN2014 A IN 9610DEN2014A IN 2014DN09610 A IN2014DN09610 A IN 2014DN09610A
Authority
IN
India
Prior art keywords
formula
ring
same
heteroatom
substituents
Prior art date
Application number
Inventor
Xiaodong Wang
Weihe Zhang
Dmitri Kireev
Dehui Zhang
Andrew Mciver
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina filed Critical Univ North Carolina
Publication of IN2014DN09610A publication Critical patent/IN2014DN09610A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Described are compounds of Formula I or Formula II: wherein: ring A is a 5 - or 6- membered heteroaryl group; dashed lines are optional double bonds; X is N or O; Y is a carbon atom or an S or N heteroatom in ring A in any suitable location; and substituents are as given herein. Compositions containing the same and methods of using the same in treating cancers such as acute lymphoblastic leukemia are also described.
IN9610DEN2014 2012-05-22 2013-05-21 IN2014DN09610A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261650000P 2012-05-22 2012-05-22
PCT/US2013/042033 WO2013177168A1 (en) 2012-05-22 2013-05-21 Pyrimidine compounds for the treatment of cancer

Publications (1)

Publication Number Publication Date
IN2014DN09610A true IN2014DN09610A (en) 2015-07-31

Family

ID=49624289

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9610DEN2014 IN2014DN09610A (en) 2012-05-22 2013-05-21

Country Status (14)

Country Link
US (1) US9567326B2 (en)
EP (1) EP2852579A4 (en)
JP (1) JP2015517574A (en)
KR (1) KR20150018789A (en)
CN (1) CN104302627A (en)
AU (1) AU2013266438B2 (en)
BR (1) BR112014028424A2 (en)
CA (1) CA2873878A1 (en)
HK (1) HK1206338A1 (en)
IL (1) IL235726A0 (en)
IN (1) IN2014DN09610A (en)
MX (1) MX2014013632A (en)
RU (1) RU2014145121A (en)
WO (1) WO2013177168A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2571361A4 (en) 2010-05-19 2013-11-13 Univ North Carolina Pyrazolopyrimidine compounds for the treatment of cancer
US9273056B2 (en) 2011-10-03 2016-03-01 The University Of North Carolina At Chapel Hill Pyrrolopyrimidine compounds for the treatment of cancer
JP2015517574A (en) 2012-05-22 2015-06-22 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Pyrimidine compounds for cancer treatment
EP2903617B1 (en) * 2012-10-08 2019-01-30 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
US9562047B2 (en) 2012-10-17 2017-02-07 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
WO2014085225A1 (en) 2012-11-27 2014-06-05 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
CN104926801B (en) * 2014-03-22 2019-06-04 浙江大学 Substituted azetidine analog derivative, the pharmaceutical composition containing it and its application in antitumor
WO2015157115A1 (en) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Mertk-specific pyrimidine compounds
US10526309B2 (en) 2015-10-02 2020-01-07 The University Of North Carolina At Chapel Hill Pan-TAM inhibitors and Mer/Axl dual inhibitors
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
CN109562113A (en) 2016-05-10 2019-04-02 C4医药公司 Loop coil degron body for target protein degradation
EP3454856A4 (en) 2016-05-10 2019-12-25 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
ES2940911T3 (en) * 2016-06-27 2023-05-12 Rigel Pharmaceuticals Inc 2,4-diamino-pyrimidine compounds and their use as IRAK4 inhibitors
CN106749173A (en) * 2016-11-25 2017-05-31 吉林化工学院 A kind of preparation method of pyrimidine bipyridyliumses compound
CN110831937A (en) * 2017-05-02 2020-02-21 韩国化学研究院 Pyrimidine derivative compound, optical isomer thereof, or pharmaceutically acceptable salt thereof, and composition for preventing or treating Tyro 3-related diseases containing same as active ingredient
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. Targeted protein degradation
WO2022059996A1 (en) * 2020-09-15 2022-03-24 서울대학교 기술지주 주식회사 Blood circulation micro in-vitro corpuscle-mediated cancer treatment composition
KR102616469B1 (en) * 2020-09-15 2023-12-28 주식회사 유엔에스바이오 Composition for treatment of circulating small extracellular vesicles-mediated cancer

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH549339A (en) * 1971-05-12 1974-05-31 Ciba Geigy Ag HERBICIDAL AGENT.
US5958930A (en) 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
WO1997049706A1 (en) 1996-06-25 1997-12-31 Novartis Ag SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
US20080248046A1 (en) 1997-03-17 2008-10-09 Human Genome Sciences, Inc. Death domain containing receptor 5
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
KR100711042B1 (en) * 2000-04-28 2007-04-24 다나베 세이야꾸 가부시키가이샤 Cyclic compounds
GB0016877D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
DE60228103D1 (en) 2001-10-02 2008-09-18 Smithkline Beecham Corp CHEMICAL COMPOUNDS
ES2373226T3 (en) * 2002-06-28 2012-02-01 Astellas Pharma Inc. DERIVATIVE OF DIAMINOPIRIMIDINCARBOXAMIDA.
DE10239042A1 (en) 2002-08-21 2004-03-04 Schering Ag New fused macrocyclic pyrimidine derivatives, useful as e.g. cyclin-dependent kinase inhibitors for treating e.g. cancer, autoimmune, cardiovascular or neurodegenerative diseases or viral infections
ES2304252T3 (en) 2003-05-28 2008-10-01 Universita Degli Studi Di Siena SUBSTITUTED DERIVATIVES IN POSITION 4 OF PIRAZOLO (3,4-D) PIRIMIDINE AND USES OF THE SAME.
US7504396B2 (en) * 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
WO2005028434A2 (en) 2003-09-18 2005-03-31 Conforma Therapeutics Corporation Novel heterocyclic compounds as hsp90-inhibitors
CA2554201C (en) 2004-01-21 2015-04-14 Emory University Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection
JP2007520559A (en) 2004-02-03 2007-07-26 アボット・ラボラトリーズ Aminobenzoxazoles as therapeutic agents
EP1713806B1 (en) 2004-02-14 2013-05-08 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1749827A4 (en) * 2004-03-30 2010-04-21 Kyowa Hakko Kirin Co Ltd Anti-tumor agent
JP4790703B2 (en) 2004-04-07 2011-10-12 武田薬品工業株式会社 Cyclic compounds
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AU2005288864B2 (en) * 2004-09-30 2012-08-23 Janssen Sciences Ireland Uc HIV inhibiting 5-heterocyclyl pyrimidines
WO2006042102A2 (en) 2004-10-05 2006-04-20 Neurogen Corporation Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
EP1710246A1 (en) 2005-04-08 2006-10-11 Schering Aktiengesellschaft Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer
WO2007032445A1 (en) 2005-09-16 2007-03-22 Kyowa Hakko Kogyo Co., Ltd. Protein kinase inhibitors
EP1937258A2 (en) 2005-09-23 2008-07-02 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
CN101321751A (en) * 2005-09-30 2008-12-10 布里斯托尔-迈尔斯·斯奎布公司 Met kinase inhibitors
US7547782B2 (en) * 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
WO2007044426A2 (en) 2005-10-06 2007-04-19 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
NZ594466A (en) 2005-12-08 2012-08-31 Medarex Inc Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
WO2007075554A2 (en) 2005-12-19 2007-07-05 Osi Pharmaceuticals, Inc. Combination of igfr inhibitor and anti-cancer agent
EP1803723A1 (en) 2006-01-03 2007-07-04 Bayer Schering Pharma Aktiengesellschaft (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximide derivatives as selective inhibitors of the aurora kinase for the treatment of cancer
US8933089B2 (en) * 2006-03-30 2015-01-13 Janssen R & D Ireland HIV inhibiting 5-amido substituted pyrimidines
WO2007125405A2 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
GB0610242D0 (en) 2006-05-23 2006-07-05 Novartis Ag Organic compounds
JO3235B1 (en) 2006-05-26 2018-03-08 Astex Therapeutics Ltd Pyrrolopyrimidine compounds and their uses
CA2680122A1 (en) 2007-03-05 2008-09-18 Kyowa Hakko Kirin Co., Ltd. Pharmaceutical composition
WO2009032694A1 (en) 2007-08-28 2009-03-12 Dana Farber Cancer Institute Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
ATE510827T1 (en) 2007-10-12 2011-06-15 Ingenium Pharmaceuticals Gmbh INHIBITORS OF PROTEIN KINASES
EP2217716A4 (en) 2007-11-09 2011-02-09 Salk Inst For Biological Studi Use of tam receptor inhibitors as antimicrobials
US8338439B2 (en) * 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
DK2361248T3 (en) * 2008-06-27 2019-01-14 Celgene Car Llc Heteroberl compounds and uses thereof
US8399206B2 (en) 2008-07-10 2013-03-19 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US20120230991A1 (en) 2008-07-29 2012-09-13 Douglas Kim Graham Methods and compounds for enhancing anti-cancer therapy
US8569466B2 (en) 2008-09-10 2013-10-29 Nnochiri Ekwuribe Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancers
US20100137313A1 (en) * 2008-10-03 2010-06-03 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
GB0819105D0 (en) 2008-10-17 2008-11-26 Chroma Therapeutics Ltd Pyrrolo-pyrimidine compounds
US8513242B2 (en) 2008-12-12 2013-08-20 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
US8765727B2 (en) 2009-01-23 2014-07-01 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
TW201102391A (en) 2009-03-31 2011-01-16 Biogen Idec Inc Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
TW201040162A (en) * 2009-05-06 2010-11-16 Portola Pharm Inc Inhibitors of JAK
EP2464661B1 (en) 2009-08-13 2018-01-17 The Johns Hopkins University Methods of modulating immune function with anti-b7-h7cr antibodies
IN2012DN02139A (en) 2009-09-10 2015-08-07 Novartis Ag
WO2011065800A2 (en) * 2009-11-30 2011-06-03 주식회사 오스코텍 Pyrimidine derivative, method for preparing same and pharmaceutical composition containing same
EP2536410B1 (en) 2010-02-18 2015-09-23 Merck Sharp & Dohme Corp. Substituted pyrimidine derivatives and their use in treating viral infections
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
EP2571361A4 (en) 2010-05-19 2013-11-13 Univ North Carolina Pyrazolopyrimidine compounds for the treatment of cancer
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
JP2014005206A (en) * 2010-10-22 2014-01-16 Astellas Pharma Inc Arylamino heterocyclic carboxamide compound
EP2640392B1 (en) 2010-11-18 2015-01-07 Kasina Laila Innova Pharmaceuticals Private Ltd. Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
US8889684B2 (en) 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
WO2012158795A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
KR20140075693A (en) * 2011-08-29 2014-06-19 인피니티 파마슈티칼스, 인코포레이티드 Heterocyclic compounds and uses thereof
MD20140023A2 (en) 2011-09-22 2014-06-30 Pfizer Inc. Pyrrolopyrimidine and purine derivatives
US9273056B2 (en) 2011-10-03 2016-03-01 The University Of North Carolina At Chapel Hill Pyrrolopyrimidine compounds for the treatment of cancer
BR112014021065A8 (en) 2012-02-21 2018-04-24 Centre Nat Rech Scient tam receptors as virus input cofactors
EP2840080B1 (en) * 2012-04-17 2017-12-06 FUJIFILM Corporation Nitrogen-containing heterocyclic compound or salt thereof
EP2838898B1 (en) 2012-04-20 2017-01-18 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
JP2015517574A (en) 2012-05-22 2015-06-22 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Pyrimidine compounds for cancer treatment
US9562047B2 (en) 2012-10-17 2017-02-07 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
WO2014085225A1 (en) 2012-11-27 2014-06-05 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
WO2015153978A1 (en) 2014-04-04 2015-10-08 The University Of North Carolina At Chapel Hill Methods for the treatment of tumors
WO2015157115A1 (en) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Mertk-specific pyrimidine compounds

Also Published As

Publication number Publication date
EP2852579A4 (en) 2015-12-30
KR20150018789A (en) 2015-02-24
AU2013266438B2 (en) 2017-09-07
IL235726A0 (en) 2015-02-01
EP2852579A1 (en) 2015-04-01
RU2014145121A (en) 2016-07-10
AU2013266438A1 (en) 2014-12-04
WO2013177168A1 (en) 2013-11-28
MX2014013632A (en) 2015-02-05
JP2015517574A (en) 2015-06-22
HK1206338A1 (en) 2016-01-08
CN104302627A (en) 2015-01-21
BR112014028424A2 (en) 2018-04-24
US20150038481A1 (en) 2015-02-05
US9567326B2 (en) 2017-02-14
CA2873878A1 (en) 2013-11-28

Similar Documents

Publication Publication Date Title
IN2014DN09610A (en)
PH12017500408A1 (en) Heteroaryl compunds as btk inhibitors and uses thereof
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
MX2018005019A (en) Benzofuran derivative, preparation method thereof and use thereof in medicine.
GEP20217330B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
MX2016006432A (en) Tetrahydro-benzodiazepinones.
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
MX367897B (en) Macrocyclic pyridazinone derivatives.
EA030199B9 (en) Therapeutically active compounds and methods of use thereof
PH12016500643A1 (en) New octahydro - cyclobuta [1,2-c;3,4-c`] dipyrrol -2- yl
PH12016500225B1 (en) Novel quinoline-substituted compound
MX2015014234A (en) 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors.
UA118666C2 (en) Novel pyrazol derivatives
PH12015501088A1 (en) Dimeric compounds
MX2014012477A (en) Pyrrolopyrazone inhibitors of tankyrase.
MY186599A (en) Substituted pyridopyrazines as novel syk inhibitors
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
PH12015501038A1 (en) Inhibitors of iap
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
MX2018001576A (en) Pyridines and their use in the treatment of cancer.
MX2019009354A (en) Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer.
MX2015016332A (en) Pyrrolotriazines as alk inhibitors.
MY170262A (en) Dicarboxylic acid compound
PH12015500399A1 (en) Azaindolines
UA112746C2 (en) Anti-Cancer Steroid Lactones Unsaturated in 7 (8)